Prospective Evaluation of Infants With Spinal Muscular Atrophy:
study id #: NCT02831296
condition: Spinal Muscular Atrophy
status: Recruiting
purpose:SPOT SMA is a prospective NIH-supported clinical study targeting pre-symptomatic or recently diagnosed infants and children with Spinal Muscular Atrophy (SMA) types 1, 2, or 3 and their healthy control siblings less than 36 months of age at the time of study enrollment. The main objective of the study is to prospectively collect longitudinal clinical outcomes and provide counseling and education to parents of newly diagnosed children. The study will assess the impact of current standard of care management paradigms and interventions on health outcomes in newly diagnosed SMA infants and children with type 1, 2 or 3 and age appropriate controls. There is no investigational drug and no specific intervention in this study. Rather, the investigators will document outcomes related to current therapies provided to participating subjects, and will educate participants about possible clinical trial opportunities.
results: https://clinicaltrials.gov/ct2/show/results/NCT02831296
last updated: February 04, 2022
-
Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiat...Spinal muscular atrophy (SMA) is an auto...
-
How One Mother Is Raising Awareness for Spinal Muscular Atrophy – A Leading Genetic Cause of Infant DeathWhen Nicole Clark’s son Brady was born...
-
A Case Series of Paediatric Patients With Spinal Muscular Atrophy Type I Undergoing Scoliosis Correction SurgerySpinal muscular atrophy is a neuromuscul...
-
Spinal Muscular Atrophy 2019: Infantile Onset Spinal Muscular Atrophyhttps://www.youtube.com/watch?v=t6UO6bKO...
-
Artist With SMA Pens Song ‘SPACES’ About Looking Beyond DisabilityA song written and performed by an artis...
-
Seattle Children’s Hospital – Spinal Muscular AtrophySeattle Children’s Neuromuscular Progr...
-
Genetic Testing for Spinal Muscular Atrophyhttps://www.youtube.com/watch?v=7x_bumsC...